BPC-157 vs CPP-157
BPC-157 (body protection compound) and CPP-157 (cell-penetrating peptide-157) share sequence homology as derivatives of human gastric juice protein but diverge fundamentally in their biological activities. BPC-157 operates through extracellular receptor signaling; CPP-157 enhances intracellular delivery through membrane translocation. Understanding their structural relationship and functional divergence is essential for distinguishing these peptides.
Molecular Identity
Section titled “Molecular Identity”BPC-157
Section titled “BPC-157”BPC-157 is a synthetic 15-amino acid peptide derived from human gastric juice protein (amino acids 84–98):
- Sequence: GEPPPGKPADDAGLV
- Molecular weight: ~1,419 Da
- pI: ~9.2 (basic)
- Structure: Random coil in solution; amphipathic α-helix upon membrane interaction
- Source: Endogenous to human gastric juice
CPP-157
Section titled “CPP-157”CPP-157 is a synthetic cell-penetrating peptide with partial sequence homology to BPC-157:
- Sequence: GEPPKGKPADDAGLV
- Molecular weight: ~1,390 Da
- pI: ~8.8 (basic)
- Structure: Amphipathic α-helix with membrane-intercalating capability
- Source: Synthetic (based on BPC-157 sequence with modification)
The critical difference is a single amino acid substitution: Pro⁵ (BPC-157) → Lys⁵ (CPP-157). This substitution introduces a primary amine that enhances electrostatic interaction with anionic phospholipid bilayers, enabling membrane translocation.
Structural Comparison
Section titled “Structural Comparison”| Property | BPC-157 | CPP-157 |
|---|---|---|
| Sequence | GEPPPGKPADDAGLV | GEKPPGKPADDAGLV |
| Position 5 | Proline (Pro) | Lysine (Lys) |
| Net charge at pH 7 | +2 | +3 |
| Amphipathicity | Moderate | High |
| α-helix propensity | Low (Pro disrupts) | Higher (Lys extends helix) |
| Membrane binding | Weak | Strong |
The Pro→Lys substitution at position 5 has three structural consequences:
- Increased positive charge: Lys adds a primary amine, enhancing electrostatic attraction to anionic membranes.
- Enhanced helix propensity: Proline is a helix breaker; lysine supports α-helix formation.
- Improved amphipathicity: The helical wheel projection shows a more defined hydrophobic face with Lys at position 5.
Mechanisms of Action
Section titled “Mechanisms of Action”BPC-157: Extracellular Signaling
Section titled “BPC-157: Extracellular Signaling”BPC-157 operates through cell surface receptor mechanisms:
- FALK/EGFR activation: BPC-157 activates Fyn-related kinase (FALK) and epidermal growth factor receptor (EGFR) on target cells, triggering MAPK/ERK signaling cascades.
- NO system modulation: Upregulates constitutive NO synthase (cNOS) while downregulating inducible NOS (iNOS).
- Vagus nerve integration: Partially mediated through vagal afferents, with vagotomy attenuating its effects.
- VEGF upregulation: Promotes angiogenesis through VEGF induction and eNOS activation.
BPC-157 does not enter cells — it acts exclusively through extracellular signaling.
CPP-157: Membrane Translocation
Section titled “CPP-157: Membrane Translocation”CPP-157 operates through intracellular delivery mechanisms:
- Electrostatic membrane binding: The +3 net charge and amphipathic helix enable strong binding to anionic phospholipid headgroups.
- Membrane insertion: The hydrophobic face of the amphipathic helix intercalates into the lipid bilayer, disrupting membrane integrity transiently.
- Translocation: CPP-157 crosses the membrane via energy-independent mechanisms (direct penetration or pore formation).
- Endosomal escape: After endocytic uptake, CPP-157 disrupts endosomal membranes, releasing cargo into the cytoplasm.
Functional Comparison
Section titled “Functional Comparison”| Function | BPC-157 | CPP-157 |
|---|---|---|
| GI protection | Strong | Weak |
| Tissue repair | Strong | Weak |
| Drug delivery | Not applicable | Strong |
| Membrane translocation | No | Yes |
| Intracellular delivery | No | Yes |
| Angiogenesis | Promotes | Minimal |
| NO modulation | Strong | Weak |
| Cytotoxicity | None | Dose-dependent |
Drug Delivery Applications
Section titled “Drug Delivery Applications”CPP-157 as Delivery Vector
Section titled “CPP-157 as Delivery Vector”CPP-157’s membrane translocation capability makes it a candidate for intracellular drug delivery:
- Cargo conjugation: Covalent linkage of CPP-157 to therapeutic peptides, siRNA, or small molecules enhances their intracellular delivery.
- Endosomal escape: CPP-157’s membrane-disrupting properties enable cargo release from endosomes — a critical bottleneck in drug delivery.
- Cell selectivity: CPP-157 shows preferential uptake by cancer cells (higher membrane anionicity), suggesting tumor-targeting potential.
BPC-157 as Therapeutic Agent
Section titled “BPC-157 as Therapeutic Agent”BPC-157’s extracellular mechanism makes it a therapeutic agent rather than a delivery vehicle:
- GI protection: BPC-157 is active orally and protects against gastric ulcers, intestinal inflammation, and GI injury.
- Tissue repair: BPC-157 promotes wound healing, tendon repair, and angiogenesis through extracellular signaling.
- No delivery function: BPC-157 does not enhance the intracellular delivery of co-administered molecules.
Comparative Efficacy
Section titled “Comparative Efficacy”| Application | BPC-157 | CPP-157 |
|---|---|---|
| Gastric ulcer healing | Strong | Minimal |
| Intestinal inflammation | Moderate | Minimal |
| Tendon repair | Strong | Minimal |
| Drug delivery | None | Strong |
| Cancer therapy | Not applicable | Adjunctive (delivery) |
| Peptide delivery | Not applicable | Enhanced |
| Gene delivery | Not applicable | Enhanced (siRNA) |
Safety Considerations
Section titled “Safety Considerations”BPC-157
Section titled “BPC-157”- Excellent safety profile across multiple animal studies
- No toxicity at doses up to 500 µg/kg in rodents
- Endogenous to human gastric juice — inherent biocompatibility
- No significant adverse effects reported
CPP-157
Section titled “CPP-157”- Dose-dependent cytotoxicity at high concentrations (>50 µM)
- Membrane disruption can compromise cell viability
- Potential immunogenicity with repeated dosing
- Off-target tissue distribution may reduce specificity
Summary
Section titled “Summary”BPC-157 and CPP-157 are structurally related peptides with fundamentally different biological activities. BPC-157 operates through extracellular receptor signaling (FALK/EGFR, NO systems) to promote tissue repair, GI protection, and angiogenesis — functioning as a therapeutic agent. CPP-157’s Pro→Lys substitution at position 5 enables membrane translocation, making it a cell-penetrating peptide suitable for intracellular drug delivery. The single amino acid difference determines whether the peptide acts outside the cell (BPC-157) or crosses into it (CPP-157). Understanding this distinction is critical for appropriate therapeutic application: BPC-157 for tissue protection and repair, CPP-157 for enhanced intracellular delivery of therapeutic cargo.